US6448323B1 - Film coatings and film coating compositions based on polyvinyl alcohol - Google Patents

Film coatings and film coating compositions based on polyvinyl alcohol Download PDF

Info

Publication number
US6448323B1
US6448323B1 US09/351,076 US35107699A US6448323B1 US 6448323 B1 US6448323 B1 US 6448323B1 US 35107699 A US35107699 A US 35107699A US 6448323 B1 US6448323 B1 US 6448323B1
Authority
US
United States
Prior art keywords
weight
range
dispersion
aqueous coating
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/351,076
Other languages
English (en)
Other versions
US20020103285A1 (en
Inventor
Martin Philip Jordan
James Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BPSI Holdings LLC
Original Assignee
BPSI Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23379470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6448323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BPSI Holdings LLC filed Critical BPSI Holdings LLC
Priority to US09/351,076 priority Critical patent/US6448323B1/en
Assigned to BPSI HOLDINGS, INC. reassignment BPSI HOLDINGS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JORDAN, MARTIN PHILIP, TALYOR, JAMES
Priority to AU71328/00A priority patent/AU766046B2/en
Priority to AT00960118T priority patent/ATE272674T1/de
Priority to CNB008100950A priority patent/CN1206267C/zh
Priority to HU0202260A priority patent/HU226963B1/hu
Priority to ES00960118T priority patent/ES2225209T3/es
Priority to DE60012754T priority patent/DE60012754T2/de
Priority to PCT/US2000/040287 priority patent/WO2001004195A1/en
Priority to IL14742500A priority patent/IL147425A0/xx
Priority to CA002374629A priority patent/CA2374629C/en
Priority to BRPI0012263-7A priority patent/BR0012263B1/pt
Priority to KR1020027000241A priority patent/KR100616732B1/ko
Priority to EP00960118A priority patent/EP1208143B1/en
Priority to JP2001509406A priority patent/JP2003509339A/ja
Priority to CZ20020066A priority patent/CZ303912B6/cs
Priority to EG20000866A priority patent/EG24436A/xx
Priority to ARP000103405A priority patent/AR025542A1/es
Priority to CO00051041A priority patent/CO5190675A1/es
Priority to TW089113503A priority patent/TWI288162B/zh
Priority to IL147425A priority patent/IL147425A/en
Priority to ZA200200104A priority patent/ZA200200104B/xx
Publication of US20020103285A1 publication Critical patent/US20020103285A1/en
Publication of US6448323B1 publication Critical patent/US6448323B1/en
Application granted granted Critical
Priority to JP2011118152A priority patent/JP2011225576A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00—Use of inorganic substances as compounding ingredients
    • C08K3/34—Silicon-containing compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/49—Phosphorus-containing compounds
    • C08K5/51—Phosphorus bound to oxygen
    • C08K5/52—Phosphorus bound to oxygen only
    • C08K5/521—Esters of phosphoric acids, e.g. of H3PO4

Definitions

  • This invention relates to the field of aqueous film coating of substrates like pharmaceutical tablets, nutritional supplements, food, confectionery forms, agricultural seeds, and the like, and is specifically concerned with coating substrates with a coating based on polyvinyl alcohol.
  • OPADRY AMB coating compositions produce film coatings having excellent moisture barrier properties.
  • the spray rate for coating pharmaceutical tablets in an O'Hara Lab Coat I coater fitted with a 24′′ pan containing 12 kilograms of tablets using a aqueous film coating solution/dispersion formed from an OPADRY AMB coating composition is slow (about 25 to 30 grams/minute compared to other types of coating systems which can be sprayed at 50 to 70 grams/min).
  • a slow spray rate is a disadvantage, such a disadvantage is outweighed by the moisture barrier properties obtained from the OPADRY AMB coating composition, for the special application when a moisture barrier film coating is required to coat a pharmaceutical substrate.
  • a slow spray rate is not acceptable due to the additional processing costs that are associated with a slow spray rate.
  • Polyethylene glycol is a known plasticizer used in film coatings to reduce the glass transition temperature of the film forming polymer and to make the polymer less brittle. Inclusion of polyethylene glycol in a coating system would be expected to result in making the coating system more tacky, as predicted by the Williams-Landel-Ferry equation. Accordingly, adding polyethylene glycol to PVA, which is already very tacky, would be expected to result in making the coating system even more tacky, thereby making the problem of tackiness of PVA even worse.
  • polyethylene glycol would be expected to compromise the moisture barrier properties of a PVA film coating.
  • Insoluble materials such as pigments, glidants, and flow aids commonly are used in film coating compositions.
  • pigment is used to provide a color to the film coating and talc is used as a glidant and a filler to reduce the percentage of the amount of other more costly components in the film coating composition.
  • Use of insoluble materials in the film coating composition may not be haphazard since, as is well recognized by those skilled in the art, adding insoluble materials to a film coating composition typically decreases the tensile strength of the film coating, which means a weaker film is obtained as the amount of insoluble materials in the film coating increases.
  • Keith et al. U.S. Pat. No. 4,432,965 discloses a sustained release oral dosage form comprising a tablet core containing a pharmaceutically effective amount of quinidine which is coated with a sustained released polymeric coating which contains about 5 to about 20% by weight polyethylene glycol and from about 80 to 95% by weight polyvinyl alcohol. Keith et al. U.S. Pat. No. 4,432,965 discloses that their sustained release coating of PVA and polyethylene glycol dissolves slowly in gastric and intestinal fluids.
  • Another object of the invention is to provide a film coating based on polyvinyl alcohol which may be sprayed onto substrates such as pharmaceutical tablets, nutritional supplements, food, confectionery forms, agricultural seeds, and the like at a coating solution spray rate of about 55 to 60 grams per minute.
  • Another object of the invention is to provide a film coating that is fast dissolving.
  • the inventive dry film coating composition for use in coating pharmaceutical tablet, nutritional supplement, food, confectionery forms, agricultural seed, and the like comprises 1) polyvinyl alcohol, 2) a plasticizer such as polyethylene glycol or glycerin, and 3) talc.
  • the inventive dry film coating composition includes one or more of the following components: a pigment/opacifier and lecithin.
  • a method of coating substrates comprises the steps of mixing 1) polyvinyl alcohol, 2) a plasticizer such as polyethylene glycol or glycerin, and 3) talc into water to form an aqueous coating dispersion, applying an effective amount of the coating dispersion onto the substrates to form a film coating on the substrates, and drying the film coating on the substrates.
  • a plasticizer such as polyethylene glycol or glycerin
  • talc talc into water to form an aqueous coating dispersion
  • one or more of the following components is/are mixed into water with the polyvinyl alcohol, the plasticizer, and the talc to form the inventive coating dispersion: a pigment/opacifier and lecithin.
  • the invention also includes the aqueous coating dispersion, the coated substrates, such as coated pharmaceutical tablets, coated nutritional supplements, coated food products, coated confectionery forms, coated agricultural seeds, and the like, and the method of making the dry film coating compositions and the method of making the coating dispersion of the invention.
  • Polyvinyl alcohol is the film former of the coating.
  • the grades of polyvinyl alcohol found useful under the invention correspond to polyvinyl alcohol that comprises partially hydrolyzed polyvinyl acetate which has a percentage of hydrolysis greater than about 86.5 mol. % and preferably in a range of about 86.5 to 89.0 mol. %.
  • the polyvinyl alcohol is micronized to facilitate dissolving the polyvinyl alcohol into the water when forming the aqueous coating solution.
  • the particle size of the micronized polyvinyl alcohol falls in the following quanities and mesh sizes: 47.8% is greater than 200 microns; 28.7% is between 200 and 145 microns; 22.9% is between 145 and 100 microns; 0.5% is between 100 and 80 microns; and 0.1% is between 80 microns.
  • the polyethylene glycol is a plasticizer for making the coating of the invention non-brittle and non-cracking.
  • Polyethylene glycol having a nominal molecular weight of greater than 1000 has been found useful, and polyethylene glycol having a molecular weight of 3000 is preferred.
  • Glycerin another plasticizer, may be substituted for the polyethylene glycol.
  • glycerin when used in the inventive coating composition, reduces the tackiness of the resultant film coating by surprisingly acting as a mild detackifier.
  • the talc is a glidant, and the talc helps improve the smoothness of the final coating since the talc facilitates the tumbling of tablets over one another during coating.
  • the talc in an amount between about 9% and about 45%, and preferably between about 9% and 20%, and more preferably at about 10%, by weight of the coating composition produces an increase in the tensile strength in the film coating, resulting in a stronger film. This is highly unexpected since it would be expected that the tensile strength of a film coating would decrease as the amount of an insoluble component, such as talc, increases in the film coating composition.
  • the pigment/opacifier may be any food approved colors, opacifiers, or dyes.
  • the pigment/opacifier may be aluminum lakes, iron oxides, titanium dioxide, or natural colors. Examples of such pigments/opacifiers are listed in Colorcon U.S. Pat. No. 4,543,570 issued Sep. 24, 1985 which is incorporated herein by reference.
  • the lecithin is a detackifier. We have found: 1) the lecithin also acts as a surfactant by helping the wetting of the components of the aqueous coating dispersion; the lecithin helps solvate the polyvinyl alcohol; and the lecithin has a plasticizing effect by locking moisture in the coating so the coating stays flexible and does not become brittle.
  • dry components of the following formulation are blended together in a dry powder mill, such as a PK blender, for 25 minutes or until an homogenous mixture is achieved, resulting in one formulation of the inventive dry film coating composition.
  • a dry powder mill such as a PK blender
  • the dry film coating composition of the invention may be granulated using a planetary mixer, such as a Hobart planetary mixer. After the dry film coating composition is loaded into the mixer and the mixer is switched on, sufficient water is slowly added until the composition forms slightly adherent granules. These granules are then passed through a 1-2 mm screen and then dried in a 30° C. oven until the moisture content is below 5%. The composition is then sieved again through a 1-2 mm screen and then is ready for use in a nondusting, granular form. If not optionally granulated, the composition may be milled such as in a hammer mill (Apex Machinery, Dartford, England), for example. Other methods of granulation which may be used are spray granulation and roller compaction.
  • a planetary mixer such as a Hobart planetary mixer.
  • 300 grams of the resulting film coating composition is dispersed into 1200 grams of distilled water to form an inventive coating dispersion (20% solids), and 1500 grams of this dispersion is sprayed onto 10 kilograms of tablets using a coater to form the inventive coating on the tablets having a theoretical weight gain of 3%.
  • the tablets are rotated in the coater at a rotation speed of 12-14 rpm.
  • Hot air at 60° C. to 70° C. is used to evaporate the water in the sprayed coating dispersion and to maintain the tablets at 38° C.-42° C.
  • the spraying rate of coating dispersion during coating is 60 grams per minute.
  • the tablets Upon completion of the coating process, the tablets show a smooth surface with excellent logo definition.
  • the film coating on the tablets possesses an excellent long-lasting shinny gloss, minimal tackiness, good film adhesion, and good tensile strength (about 10-15 MPa).
  • each formulation is mixed together, formed into a coating solution, and applied to tablets, as in Example 1, to obtain film coatings possessing a smooth surface, an excellent long-lasting shinny gloss, minimal tackiness, good film adhesion, and good tensile strength typically between about 10 MPa and about 16 MPa.
  • the dry ingredients of the above formulation are loaded into a suitably-sized food processor and blended vigorously for 5 minutes until homogeneous. After 5 minutes, the liquid portion of the formulation (glycerin, a plasticizer), is added to the processor and blending continues for an additional 3 minutes to create a dry coating composition of the invention. 90 grams of this formulation is then dispersed into 360 grams of purified water and stirred for 45 minutes to form an aqueous coating dispersion of 20.0% solids that is ready for spray coating.
  • a 3.0 kilogram charge of mixed tablets consisting of 2.0 kg of 3 ⁇ 8′′ standard concave placebos and 1.0 kg of 5 grain aspirin cores of similar diameter is loaded into a 15′′ O'Hara Labcoat I coating pan with 4 mixing baffles and 6 anti-slide bars.
  • the aqueous coating dispersion is sprayed onto the tablet bed using 1 Spraying System Gun, 1 ⁇ 8 VAU SS and a Masterflex digital console peristaltic pump with 1 7518-02 pumphead.
  • the atomizing air is 25 psi
  • pattern air is 35 psi
  • inlet air temperature is 70° C.
  • outlet air is 48° C.
  • the tablet bed temperature remains at 41° C.
  • the pan speed is 16 rpm
  • the coating liquid feed rate is 20 g/min (which is equivalent to 50-60 grams/minute in the O'Hara Lab Coat I coater fitted with a 24′′ pan)
  • the total coating time is 22 minutes.
  • a theoretical 3.0% dry coating weight gain is applied and the film coating on the tablets possesses an excellent long-lasting shiny gloss, minimal tackiness, good adhesion, and good tensile strength (about 10-15 MPa).
  • inventive aqueous coating dispersion it also may be prepared by adding the individual components of the inventive coating composition directly into water and then mixing to form the coating dispersion.
  • the coating dispersion is prepared at a solids level of between 10% and 30%.
  • coating solution spray rates of about 60 grams/minute (in a 24′′ pan containing 12 kilograms of tablets) may be obtained using the aqueous coating dispersions of the invention. This is unexpected because, to those skilled in the art, it is known that very tacky polymers require slow spray rates due to their tackiness. Accordingly, PVA, being a very tacky polymer, would be expected to require slow spray rates. For instance, coating solutions formed from Colorcon's PVA-based OPADRY AMB coating compositions require a slow spray rate (e.g., 25-30 grams/minute in a 24′′ pan containing 12 kilograms of tablets) due to the tackiness of PVA in the coating solution.
  • a slow spray rate e.g., 25-30 grams/minute in a 24′′ pan containing 12 kilograms of tablets
  • talc which is an insoluble material in the inventive coating composition used as a glidant and a filler, in the inventive film coating composition in an amount between about 9% and about 45%, and preferably between about 9% and 20%, and more preferably at about 10%, by weight of the coating composition and in the inventive film coating dispersion in an amount between about 9% and about 45%, and preferably between about 9% and 20%, and more preferably about 10%, by weight of the non-water ingredients of the film coating dispersion produces an increase in the tensile strength of the film coating, rather than decreasing the tensile strength. Accordingly, in accordance with the invention, talc may be used in amounts that reduce the amount of PVA in the film coating, thereby reducing the cost of the film
  • the inventive coating has good moisture barrier properties. This, too, is surprising and unexpected because polyethylene glycol and similar plasticizers are hydrophilic and would be expected to reduce the moisture barrier properties of PVA. While the water vapor transmission rate for a film coating made from an OPADRY film coating composition comprising hydroxypropyl methylcellulose and polyethylene glycol is about 40, and the water vapor transmission rate for a film coating made from an OPADRY AMB coating composition not having any polyethyelene glycol in it is about 6, the water vapor transmission rate for a film coating made in accordance with the invention is about 10.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Confectionery (AREA)
  • Paints Or Removers (AREA)
US09/351,076 1999-07-09 1999-07-09 Film coatings and film coating compositions based on polyvinyl alcohol Expired - Lifetime US6448323B1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
US09/351,076 US6448323B1 (en) 1999-07-09 1999-07-09 Film coatings and film coating compositions based on polyvinyl alcohol
IL14742500A IL147425A0 (en) 1999-07-09 2000-06-30 Film coatings and film coating compositions based on polyvinyl alcohol
KR1020027000241A KR100616732B1 (ko) 1999-07-09 2000-06-30 폴리비닐 알코올 기제의 피막 코팅재 및 피막 코팅 조성물
CZ20020066A CZ303912B6 (cs) 1999-07-09 2000-06-30 Suchá filmotvorná potahová kompozice, kapalná disperze a zpusob potahování substrátu
CNB008100950A CN1206267C (zh) 1999-07-09 2000-06-30 基于聚乙烯醇的薄膜包衣和薄膜包衣组合物
HU0202260A HU226963B1 (en) 1999-07-09 2000-06-30 Dry film coating composition and method of coating subsrates using it
ES00960118T ES2225209T3 (es) 1999-07-09 2000-06-30 Peliculas de recubrimiento y composiciones basadas en poli(alcohol vinilico) para peliculas de recubrimiento.
DE60012754T DE60012754T2 (de) 1999-07-09 2000-06-30 Filmbeschichtungen und filmbeschichtungszusammensetzungen basierend auf polyvinylalkohol
PCT/US2000/040287 WO2001004195A1 (en) 1999-07-09 2000-06-30 Film coatings and film coating compositions based on polyvinyl alcohol
AT00960118T ATE272674T1 (de) 1999-07-09 2000-06-30 Filmbeschichtungen und filmbeschichtungszusammensetzungen basierend auf polyvinylalkohol
CA002374629A CA2374629C (en) 1999-07-09 2000-06-30 Film coatings and film coating compositions based on polyvinyl alcohol
BRPI0012263-7A BR0012263B1 (pt) 1999-07-09 2000-06-30 composição de pelìcula de revestimento, seca, para uso em revestimento de tabletes farmacêuticos, suplementos nutricionais, alimentos, formas de confeitaria, sementes agrìcolas, e, similares; método de revestimento de substratos como estes, com uma pelìcula de revestimento.
AU71328/00A AU766046B2 (en) 1999-07-09 2000-06-30 Film coatings and film coating compositions based on polyvinyl alcohol
EP00960118A EP1208143B1 (en) 1999-07-09 2000-06-30 Film coatings and film coating compositions based on polyvinyl alcohol
JP2001509406A JP2003509339A (ja) 1999-07-09 2000-06-30 フィルムコーティングおよびポリビニルアルコールをベースとするフィルムコーティング組成物
EG20000866A EG24436A (en) 1999-07-09 2000-07-02 Film coatings and film coating compositions based on polyvinyl alcohol
ARP000103405A AR025542A1 (es) 1999-07-09 2000-07-04 Composicion de revestimiento de pelicula seca para uso en el revestimiento de tabletas farmaceuticas, suplementos nutricionales, alimentos, formas de confituras, semillas agricolas y similares, dispersion de revestimiento de pelicula liquida formada a partir de dicha composicion de revestimiento de
CO00051041A CO5190675A1 (es) 1999-07-09 2000-07-07 Revestimientos de pelicula y composiciones para revestimien- tos de peliculas basadas en alcohol polivinilico
TW089113503A TWI288162B (en) 1999-07-09 2000-07-07 Film coatings and film coating compositions based on polyvinyl alcohol
IL147425A IL147425A (en) 1999-07-09 2001-12-31 Film coatings and film coating compositions based on polyvinyl alcohol
ZA200200104A ZA200200104B (en) 1999-07-09 2002-01-04 Film coatings and film coating compositions based on polyvinyl alcohol.
JP2011118152A JP2011225576A (ja) 1999-07-09 2011-05-26 フィルムコーティングおよびポリビニルアルコールをベースとするフィルムコーティング組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/351,076 US6448323B1 (en) 1999-07-09 1999-07-09 Film coatings and film coating compositions based on polyvinyl alcohol

Publications (2)

Publication Number Publication Date
US20020103285A1 US20020103285A1 (en) 2002-08-01
US6448323B1 true US6448323B1 (en) 2002-09-10

Family

ID=23379470

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/351,076 Expired - Lifetime US6448323B1 (en) 1999-07-09 1999-07-09 Film coatings and film coating compositions based on polyvinyl alcohol

Country Status (20)

Country Link
US (1) US6448323B1 (cs)
EP (1) EP1208143B1 (cs)
JP (2) JP2003509339A (cs)
KR (1) KR100616732B1 (cs)
CN (1) CN1206267C (cs)
AR (1) AR025542A1 (cs)
AT (1) ATE272674T1 (cs)
AU (1) AU766046B2 (cs)
BR (1) BR0012263B1 (cs)
CA (1) CA2374629C (cs)
CO (1) CO5190675A1 (cs)
CZ (1) CZ303912B6 (cs)
DE (1) DE60012754T2 (cs)
EG (1) EG24436A (cs)
ES (1) ES2225209T3 (cs)
HU (1) HU226963B1 (cs)
IL (2) IL147425A0 (cs)
TW (1) TWI288162B (cs)
WO (1) WO2001004195A1 (cs)
ZA (1) ZA200200104B (cs)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040105896A1 (en) * 1997-09-19 2004-06-03 Crosfield Limited Metal compunds, mixed or sulphated, as phosphate binders
US20050016739A1 (en) * 2001-06-20 2005-01-27 Weatherford/Lamb, Inc. Tie back and method for use with expandable tubulars
EP1512331A1 (de) * 2003-09-02 2005-03-09 IPC Process Center GmbH & Co. Nahrungsergänzungsmittel
WO2005089719A1 (en) * 2004-02-25 2005-09-29 Ideal Cures Pvt.Ltd. Polish compositions
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088585A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070102130A1 (en) * 2005-11-04 2007-05-10 Satyavolu Jagannadh V Lecithin-containing starch compositions, preparation thereof and paper products having oil and grease resistance, and/or release properties
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
US20080145493A1 (en) * 2006-12-14 2008-06-19 Sensient Colors Inc. Pearlescent pigment compositions and methods for making and using the same
US20090317459A1 (en) * 2006-01-31 2009-12-24 Ineos Healthcare Limited Material
US20100029788A1 (en) * 2006-09-29 2010-02-04 John Pelesko Wet edible pearlescent film coatings
US20100068274A1 (en) * 2007-04-26 2010-03-18 Eisai R & D Management Co., Ltd. Process for production of tablet
US20100203152A1 (en) * 2007-07-27 2010-08-12 Ineos Healthcare Kimited Mixed metal compounds used as antacids
US20100215770A1 (en) * 2007-10-16 2010-08-26 Maurice Sydney Newton Mixed metal compounds for treatment of hyperphosphataemia
US20100291183A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
US20100291159A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Film coatings containing fine particle size detackifiers and substrates coated therewith
US20110086329A1 (en) * 2004-11-10 2011-04-14 Ranir/Dcp Corporation Device and method for delivering an oral care agent
US7931778B2 (en) 2005-11-04 2011-04-26 Cargill, Incorporated Lecithin-starches compositions, preparation thereof and paper products having oil and grease resistance, and/or release properties
US20130064887A1 (en) * 2011-03-07 2013-03-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US20130156855A1 (en) * 2011-12-16 2013-06-20 Aviv Ben-Menachem Acne treatment
US20130164376A1 (en) * 2011-12-27 2013-06-27 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
US20130236543A1 (en) * 2012-03-07 2013-09-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US8753668B2 (en) 2005-05-05 2014-06-17 Sensient Flavors Llc Production of beta-glucans and mannans
WO2014130653A1 (en) 2013-02-22 2014-08-28 Valent U.S.A. Corporations Seed treatment formulations
US9066917B2 (en) 2009-08-03 2015-06-30 Cytochroma Development Inc. Mixed metal compound
US9101131B2 (en) 2007-12-03 2015-08-11 Valent U.S.A., Corporation Seed treatment formulations
US20150284901A1 (en) * 2014-04-02 2015-10-08 Kraton Polymers Us Llc Textile coating composition
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US20170014422A1 (en) * 2014-02-14 2017-01-19 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph iv
US9566302B2 (en) 2010-02-04 2017-02-14 Opko Ireland Global Holdings, Ltd. Composition comprising mixed metal compounds and xanthan gum
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
KR20170093643A (ko) * 2016-02-05 2017-08-16 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US20180371383A1 (en) * 2015-12-04 2018-12-27 Eurotab Coated detergent tablet
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10604318B2 (en) 2013-06-04 2020-03-31 Monosol, Llc Method for sealing a water-soluble film by applying a sealing solution
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11168485B2 (en) 2018-09-15 2021-11-09 VBBT Corp. Low cost emergency housing
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US12312352B2 (en) 2012-05-14 2025-05-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in SIRS and/or sepsis

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241797A (ja) * 2001-02-20 2002-08-28 Kao Corp 洗濯用物品
DE10207427A1 (de) 2002-02-21 2003-09-04 Basf Ag Schnelllöslicher Filmüberzug basierend auf Polyvinylalkohol-Polyether-Pfropfcopolymeren in Kombination mit Hydroxy-, Amid-, oder Esterfunktionen enthaltenden Komponenten
DE10211195B4 (de) * 2002-03-11 2009-01-02 Ipc Process Center Gmbh Nahrungsergänzungsmittel
JP4549609B2 (ja) * 2002-04-11 2010-09-22 エスエス製薬株式会社 被覆固形催眠製剤
US8956160B2 (en) * 2002-07-02 2015-02-17 Ranir, Llc Device and method for delivering an oral care agent
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
JP4680061B2 (ja) * 2003-08-20 2011-05-11 塩野義製薬株式会社 新規コーティング組成物
DK1696738T3 (da) * 2003-12-12 2008-09-01 Basf Se Fremgangsmåde og middel til overfladebehandling af levnedsmidler
DE102004031835A1 (de) 2004-06-30 2006-01-19 Basf Ag Schnelldispergierbares, feinteiliges, nicht zur Entmischung neigendes pulverförmiges Filmüberzugsmittel basierend auf Polyvinylalkohol-Polyether-Pfropfcopolymeren gekennzeichnet durch besondere physikalische Stabilität und niedrige Rauhigkeit
TW200800233A (en) * 2006-04-28 2008-01-01 Shionogi & Amp Co Ltd A coated preparation of macrolide antibiotics
JP5162141B2 (ja) * 2007-02-20 2013-03-13 エスエス製薬株式会社 フィルムコーティング用組成物
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
US8772358B2 (en) 2008-11-12 2014-07-08 Archer Daniels Midland Co. Lecithin and plasticizer compositions and methods
US10294376B2 (en) * 2008-11-12 2019-05-21 Archer Daniels Midland Company Lecithin and plasticizer compositions and methods
EP2193710B1 (en) * 2008-12-05 2014-04-09 Patent 06-001 B.V. Coating for lily bulbs
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
TWI455733B (zh) * 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
BR112012014328B1 (pt) 2009-12-16 2021-06-15 Basf Se Composição de revestimento de película, forma de dosagem fornecida com um revestimento de película, e, uso das composições de revestimento de película
US8414905B2 (en) 2009-12-16 2013-04-09 Basf Se Film coating compositions based on polyvinyl alcohol-polyether graft copolymer/polyvinyl alcohol combinations with an improved moisture barrier effect
JP5853699B2 (ja) 2010-08-31 2016-02-09 東レ株式会社 医薬固形製剤用のコーティング剤、医薬用フィルム製剤及び被覆医薬固形製剤
US8715729B2 (en) 2010-12-22 2014-05-06 Basf Se Rapidly disintegrating, solid coated dosage form
JP5916091B2 (ja) * 2012-01-31 2016-05-11 大原薬品工業株式会社 口腔内崩壊錠のｕｖレーザー印刷方法
EP2671571A1 (en) * 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-release formulations of clarithromycin
WO2014030204A1 (ja) * 2012-08-20 2014-02-27 大日本住友製薬株式会社 薬物含有中空粒子
AT513519B1 (de) 2012-10-23 2014-07-15 Gebro Holding Gmbh Filmbeschichtungszusammensetzung
US20140272368A1 (en) * 2013-03-13 2014-09-18 Celanese Acetate Llc Cellulose diester films for playing cards
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
FR3004070B1 (fr) * 2013-04-05 2015-07-31 Bel Fromageries Procede d'enrobage de produits fromagers
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
NO3043778T3 (cs) * 2013-09-13 2018-02-03
HUE049598T2 (hu) * 2014-01-21 2020-09-28 Bpsi Holdings Llc Közepes láncú glicerideket tartalmazó, közvetlen kibocsátású film bevonatok, és az ezekkel bevont hordozók
CN103948672B (zh) * 2014-05-05 2020-06-12 南宁富莱欣生物科技有限公司 一种包衣片剂及其生产方法
US20170348243A1 (en) 2015-01-01 2017-12-07 Ideal Cures Pvt. Ltd. Novel film coating composition
HUE061213T2 (hu) * 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
WO2016172699A1 (en) * 2015-04-24 2016-10-27 International Flavors & Fragrances Inc. Delivery systems and methods of preparing the same
KR102158339B1 (ko) * 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제
CN107259580B (zh) * 2017-07-17 2018-06-19 武汉维奥制药有限公司 一种多种矿物质维生素制剂的制备方法
JP7189689B2 (ja) * 2018-06-25 2022-12-14 日本酢ビ・ポバール株式会社 コーティング組成物並びに経口固形剤及びその製造方法
GB201918030D0 (en) * 2019-12-09 2020-01-22 Synthomer Uk Ltd Improvements in, or relating to, binders and/or coatings

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
JPS5428812A (en) 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
JPS5549312A (en) 1978-10-03 1980-04-09 Sankyo Co Ltd Preparation of slow-releasing medicine
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
JPS5942325A (ja) 1982-09-03 1984-03-08 Dai Ichi Seiyaku Co Ltd コ−テイング用組成物及びコ−テイング製剤
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4665648A (en) * 1983-07-06 1987-05-19 Seppic Sa Film-forming compositions for enveloping grains and seeds
US4683256A (en) 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
JPH0859512A (ja) 1994-08-25 1996-03-05 Morishita Roussel Kk フィルムコーティング組成物およびそれを用いた固形製剤
US5697922A (en) * 1992-11-20 1997-12-16 Pfizer Inc. Delivery device having encapsulated excipients
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
US5885617A (en) * 1994-07-12 1999-03-23 Bpsi Holdings, Inc. Moisture barrier film coating composition, method, and coated form

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1216486B (de) * 1964-04-23 1966-05-12 Merck Ag E Verfahren zur Herstellung von Dragees
JP3059200B2 (ja) * 1990-09-27 2000-07-04 株式会社クラレ 易崩壊性樹脂組成物
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5322866A (en) * 1993-01-29 1994-06-21 The United States Of America As Represented By The Secretary Of The Army Method of producing biodegradable starch-based product from unprocessed raw materials
CN1097619C (zh) * 1994-07-12 2003-01-01 伯温德药品服务公司 隔潮膜涂层组合物及其生产方法以及涂层制品
JPH092976A (ja) * 1995-06-20 1997-01-07 Lion Corp 被覆組成物

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
JPS5428812A (en) 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
JPS5549312A (en) 1978-10-03 1980-04-09 Sankyo Co Ltd Preparation of slow-releasing medicine
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4432965A (en) * 1982-07-09 1984-02-21 Key Pharmaceuticals, Inc. Quinidine sustained release dosage formulation
JPS5942325A (ja) 1982-09-03 1984-03-08 Dai Ichi Seiyaku Co Ltd コ−テイング用組成物及びコ−テイング製剤
US4665648A (en) * 1983-07-06 1987-05-19 Seppic Sa Film-forming compositions for enveloping grains and seeds
US5697922A (en) * 1992-11-20 1997-12-16 Pfizer Inc. Delivery device having encapsulated excipients
US5885617A (en) * 1994-07-12 1999-03-23 Bpsi Holdings, Inc. Moisture barrier film coating composition, method, and coated form
JPH0859512A (ja) 1994-08-25 1996-03-05 Morishita Roussel Kk フィルムコーティング組成物およびそれを用いた固形製剤
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
An Application of Tack Measurement to Fluidized Bed Coating, by L.S.C. Wan and W.F. Lai, Department of Pharmacy, University of Singapore,(Feb. 27, 1992).
Drug Development and Industrial Pharmacy, 17 (12), 1655-1683 (1991), "Preparation and Evaluation of Eudragit Acrylic Resin for Controlled Drug Release of Pseudoephedrin Hydrochloride" by Shun Por Li, Kenneth M. Feld, and Chane R. Kowarski.
Effects of Plasticizers and Titanium Dioxide on the Properties of Polyvinylalcohol Coatings Used in Enzyme Granules, M.S. Gerbert, E.R. Hsu, M.J. Flynn, N.T. Becker and A.L. Gaertner, Proceed Int'l. Symp. Control. Ref. Bioact. Mater., 26, Controlled Release Society, Inc., (1999).
The Effects of Pigment Type and Concentration on the Incidence of Edge Splitting on Film-coating Tablets, by R.C. Rowe, Pharm. Acta Helv. 57 Nr. 8, pp. 221-225, (1982).

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014301A1 (en) * 1997-09-19 2011-01-20 Ineos Healthcare Limited Metal compounds, mixed or sulphated, as phosphate binders
US8568792B2 (en) 1997-09-19 2013-10-29 Cytochroma Development Inc. Metal compounds, mixed or sulphated, as phosphate binders
US7799351B2 (en) 1997-09-19 2010-09-21 Ineos Healthcare Limited Metal compounds, mixed or sulphated, as phosphate binders
US9242869B2 (en) 1997-09-19 2016-01-26 Opko Ireland Global Holdings, Ltd. Metal compounds mixed or sulphated, as phosphate binders
US20040105896A1 (en) * 1997-09-19 2004-06-03 Crosfield Limited Metal compunds, mixed or sulphated, as phosphate binders
US20050016739A1 (en) * 2001-06-20 2005-01-27 Weatherford/Lamb, Inc. Tie back and method for use with expandable tubulars
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1512331A1 (de) * 2003-09-02 2005-03-09 IPC Process Center GmbH & Co. Nahrungsergänzungsmittel
WO2005089719A1 (en) * 2004-02-25 2005-09-29 Ideal Cures Pvt.Ltd. Polish compositions
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
WO2006047738A2 (en) 2004-10-27 2006-05-04 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088585A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
US8944819B2 (en) 2004-11-10 2015-02-03 Ranir, Llc Device and method for delivering an oral care agent
US20110086329A1 (en) * 2004-11-10 2011-04-14 Ranir/Dcp Corporation Device and method for delivering an oral care agent
US8753668B2 (en) 2005-05-05 2014-06-17 Sensient Flavors Llc Production of beta-glucans and mannans
US20070102130A1 (en) * 2005-11-04 2007-05-10 Satyavolu Jagannadh V Lecithin-containing starch compositions, preparation thereof and paper products having oil and grease resistance, and/or release properties
US7931778B2 (en) 2005-11-04 2011-04-26 Cargill, Incorporated Lecithin-starches compositions, preparation thereof and paper products having oil and grease resistance, and/or release properties
US8192845B2 (en) 2005-11-04 2012-06-05 Cargill, Incorported Lecithin-containing starch compositions, preparation thereof and paper products having oil and grease resistance, and/or release properties
US20090317459A1 (en) * 2006-01-31 2009-12-24 Ineos Healthcare Limited Material
US9907816B2 (en) 2006-01-31 2018-03-06 Opko Ireland Global Holdings, Ltd. Water-insoluble, iron-containing mixed metal, granular material
US9168270B2 (en) 2006-01-31 2015-10-27 Opko Ireland Global Holdings, Ltd. Water-insoluble, iron-containing mixed metal, granular material
US12171767B2 (en) 2006-05-04 2024-12-24 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US12178819B2 (en) 2006-05-04 2024-12-31 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US20100029788A1 (en) * 2006-09-29 2010-02-04 John Pelesko Wet edible pearlescent film coatings
US20080145493A1 (en) * 2006-12-14 2008-06-19 Sensient Colors Inc. Pearlescent pigment compositions and methods for making and using the same
US11375732B2 (en) 2006-12-14 2022-07-05 Sensient Colors Llc Pearlescent pigment compositions and methods for making and using the same
US20100068274A1 (en) * 2007-04-26 2010-03-18 Eisai R & D Management Co., Ltd. Process for production of tablet
US20100203152A1 (en) * 2007-07-27 2010-08-12 Ineos Healthcare Kimited Mixed metal compounds used as antacids
US10201501B2 (en) 2007-07-27 2019-02-12 Opko Ireland Global Holdings, Ltd. Mixed metal compounds used as antacids
US20100215770A1 (en) * 2007-10-16 2010-08-26 Maurice Sydney Newton Mixed metal compounds for treatment of hyperphosphataemia
US10155040B2 (en) 2007-10-16 2018-12-18 Opko Ireland Global Holdings, Ltd. Mixed metal compounds for treatment of hyperphosphataemia
US9101131B2 (en) 2007-12-03 2015-08-11 Valent U.S.A., Corporation Seed treatment formulations
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US12115179B2 (en) 2009-02-13 2024-10-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US10406172B2 (en) 2009-02-13 2019-09-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2010132205A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Film coatings containing fine particle size detackifiers and substrates coated therewith
RU2528095C2 (ru) * 2009-05-12 2014-09-10 БиПиЭсАй ХОЛДИНГЗ, ЭлЭлСи. Системы пленочного покрытия для препаратов с немедленным высвобождением, создающие усиленный барьер от влаги, и субстраты с таким покрытием
US20100291159A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Film coatings containing fine particle size detackifiers and substrates coated therewith
US9028862B2 (en) 2009-05-12 2015-05-12 Bpsi Holdings, Llc Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
US8647645B2 (en) 2009-05-12 2014-02-11 Bpsi Holdings, Llc Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
US20100291183A1 (en) * 2009-05-12 2010-11-18 Bpsi Holdings, Llc. Enhanced moisture barrier immediate release film coating systems and substrates coated therewith
US8388983B2 (en) * 2009-05-12 2013-03-05 Bpsi Holdings, Llc Film coatings containing fine particle size detackifiers and substrates coated therewith
US9066917B2 (en) 2009-08-03 2015-06-30 Cytochroma Development Inc. Mixed metal compound
US9314481B2 (en) 2009-08-03 2016-04-19 Opko Ireland Global Holdings, Ltd. Method
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9566302B2 (en) 2010-02-04 2017-02-14 Opko Ireland Global Holdings, Ltd. Composition comprising mixed metal compounds and xanthan gum
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20180185291A1 (en) 2011-03-07 2018-07-05 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US10596120B2 (en) 2011-03-07 2020-03-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US11564886B2 (en) 2011-03-07 2023-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US20130064887A1 (en) * 2011-03-07 2013-03-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US20130156855A1 (en) * 2011-12-16 2013-06-20 Aviv Ben-Menachem Acne treatment
US20130164376A1 (en) * 2011-12-27 2013-06-27 Celgene Corporation Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
EP2797581B1 (en) 2011-12-27 2020-05-06 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130236543A1 (en) * 2012-03-07 2013-09-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US12312352B2 (en) 2012-05-14 2025-05-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in SIRS and/or sepsis
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
WO2014130653A1 (en) 2013-02-22 2014-08-28 Valent U.S.A. Corporations Seed treatment formulations
US10604318B2 (en) 2013-06-04 2020-03-31 Monosol, Llc Method for sealing a water-soluble film by applying a sealing solution
US20170014422A1 (en) * 2014-02-14 2017-01-19 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph iv
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US10047477B2 (en) * 2014-04-02 2018-08-14 Kraton Polymers U.S. Llc Textile coating composition
US20150284901A1 (en) * 2014-04-02 2015-10-08 Kraton Polymers Us Llc Textile coating composition
US20180371383A1 (en) * 2015-12-04 2018-12-27 Eurotab Coated detergent tablet
US10927330B2 (en) * 2015-12-04 2021-02-23 Eurotab Coated detergent tablet
US20190083409A1 (en) * 2016-02-05 2019-03-21 Korea United Pharm, Inc. Oral composite formulation comprising fat-soluble drug and solid preparation coated with oil repellent base
KR20170093643A (ko) * 2016-02-05 2017-08-16 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US11033505B2 (en) * 2016-02-05 2021-06-15 Korea United Pharm, Inc. Oral complex preparation comprising fat-soluble drug and solid preparation coated with oil-proof material
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US12364700B2 (en) 2016-06-10 2025-07-22 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US11168485B2 (en) 2018-09-15 2021-11-09 VBBT Corp. Low cost emergency housing

Also Published As

Publication number Publication date
IL147425A (en) 2006-08-01
CN1360612A (zh) 2002-07-24
CZ303912B6 (cs) 2013-06-26
AU7132800A (en) 2001-01-30
EP1208143A1 (en) 2002-05-29
JP2003509339A (ja) 2003-03-11
WO2001004195A8 (en) 2001-10-04
CN1206267C (zh) 2005-06-15
BR0012263B1 (pt) 2010-11-16
DE60012754T2 (de) 2005-09-01
IL147425A0 (en) 2002-08-14
EP1208143A4 (en) 2002-10-30
HUP0202260A2 (en) 2002-11-28
TWI288162B (en) 2007-10-11
JP2011225576A (ja) 2011-11-10
DE60012754D1 (de) 2004-09-09
AU766046B2 (en) 2003-10-09
ZA200200104B (en) 2003-06-25
CZ200266A3 (cs) 2002-07-17
EP1208143B1 (en) 2004-08-04
BR0012263A (pt) 2002-03-12
EG24436A (en) 2009-06-25
ATE272674T1 (de) 2004-08-15
HU226963B1 (en) 2010-03-29
US20020103285A1 (en) 2002-08-01
WO2001004195A1 (en) 2001-01-18
AR025542A1 (es) 2002-12-04
CA2374629A1 (en) 2001-01-18
KR100616732B1 (ko) 2006-08-28
ES2225209T3 (es) 2005-03-16
KR20020029073A (ko) 2002-04-17
CA2374629C (en) 2009-05-19
CO5190675A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
US6448323B1 (en) Film coatings and film coating compositions based on polyvinyl alcohol
US5393333A (en) Film-forming product for coating solid forms, process for its manufacture and products coated with this film-forming product
US6420473B1 (en) Acrylic enteric coating compositions
US5630871A (en) Film coatings and film coating compositions based on cellulosic polymers and lactose
KR101783945B1 (ko) 향상된 수분차단 속방출형 필름의 코팅 시스템 및 이에 의하여 코팅된 기재
CN1330379C (zh) 可食用pga涂层组合物
US6500462B1 (en) Edible MCC/PGA coating composition
US20240024247A1 (en) High opacity coatings and substrates coated therewith
WO2006111980A2 (en) Pva based film coating and film coating compositions
US20090054533A1 (en) Film coating compositions based on tribasic calcium phosphate
EP1272165B1 (en) Acrylic enteric coating compositions
WO2006111981A2 (en) Film coating compositions and methods providing moisture barrier
US20080033059A1 (en) Enteric Coating Compositions
MXPA02000308A (en) Film coatings and film coating compositions based on polyvinyl alcohol
WO2009024992A2 (en) Film coating compositions based on tribasic calcium phosphate

Legal Events

Date Code Title Description
AS Assignment

Owner name: BPSI HOLDINGS, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JORDAN, MARTIN PHILIP;TALYOR, JAMES;REEL/FRAME:010520/0692

Effective date: 20000121

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12